...
首页> 外文期刊>Indian heart journal >A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer
【24h】

A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer

机译:随机相2试验对抗阉割前列腺癌中的地塞米松与泼尼松龙

获取原文
获取原文并翻译 | 示例
           

摘要

? 2014 European Association of Urology. All rights reserved. ? 2014 European Association of Urology. All rights reserved. Background Prednisolone is widely used as secondary hormonal treatment for castration-resistant prostate cancer (CRPC). We hypothesised that dexamethasone, another corticosteroid, is more active. Objective To compare the activity of prednisolone and dexamethasone in CRPC. Design, setting, and participants This single-centre, randomised, phase 2 trial was performed in 82 men with chemotherapy-na?ve CRPC enrolled from 2006 to 2010. Intervention Prednisolone 5 mg twice daily versus dexamethasone 0.5 mg once daily versus intermittent dexamethasone 8 mg twice daily on days 1-3 every 3 wk. Outcome measurements and statistical analysis The main end point was prostate-specific antigen (PSA) response rate. Secondary end points included time to PSA progression, radiologic response rate using Response Evaluation Criteria In Solid Tumors (RECIST), and safety. Results and limitations The intermittent dexamethasone arm was dropped after no response was seen in seven patients. By intention to treat, confirmed PSA response was seen in 41% versus 22% for daily dexamethasone versus prednisolone, respectively (p = 0.08). In evaluable patients, the PSA response rates were 47% versus 24% for dexamethasone and prednisolone, respectively (p = 0.05). Median time to PSA progression was 9.7 mo on dexamethasone versus 5.1 mo on prednisolone (hazard ratio: 1.6; 95% confidence interval, 0.9-2.8). In 43 patients with measurable disease, the response rate by RECIST was 15% and 6% for dexamethasone and prednisolone, respectively (p = 0.6). Of 23 patients who crossed over at PSA progression on prednisolone, 7 of the 19 evaluable (37%) had a confirmed PSA response to dexamethasone. Clinically significant toxicities were rare. Conclusions Dexamethasone may be more active than prednisolone in CRPC. In the absence of more definitive trials, dexamethasone should be used in preference to prednisolone. Patient summary We compared two different steroids used for treating men with advanced prostate cancer. Our results suggest that dexamethasone may be more effective than prednisolone and that both are well tolerated. Clinical trial registry EUDRAC 2005-006018-16 Background Prednisolone is widely used as secondary hormonal treatment for castration-resistant prostate cancer (CRPC). We hypothesised that dexamethasone, another corticosteroid, is more active. Objective To compare the activity of prednisolone and dexamethasone in CRPC. Design, setting, and participants This single-centre, randomised, phase 2 trial was performed in 82 men with chemotherapy-na?ve CRPC enrolled from 2006 to 2010. Intervention Prednisolone 5 mg twice daily versus dexamethasone 0.5 mg once daily versus intermittent dexamethasone 8 mg twice daily on days 1-3 every 3 wk. Outcome measurements and statistical analysis The main end point was prostate-specific antigen (PSA) response rate. Secondary end points included time to PSA progression, radiologic response rate using Response Evaluation Criteria In Solid Tumors (RECIST), and safety. Results and limitations The intermittent dexamethasone arm was dropped after no response was seen in seven patients. By intention to treat, confirmed PSA response was seen in 41% versus 22% for daily dexamethasone versus prednisolone, respectively (p = 0.08). In evaluable patients, the PSA response rates were 47% versus 24% for dexamethasone and prednisolone, respectively (p = 0.05). Median time to PSA progression was 9.7 mo on dexamethasone versus 5.1 mo on prednisolone (hazard ratio: 1.6; 95% confidence interval, 0.9-2.8). In 43 patients with measurable disease, the response rate by RECIST was 15% and 6% for dexamethasone and prednisolone, respectively (p = 0.6). Of 23 patients who crossed over at PSA progression on prednisolone, 7 of the 19 evaluable (37%) had a confirmed PSA response to dexamethasone. Clinically significant toxicities were
机译:还2014年欧洲泌尿外科协会。版权所有。还2014年欧洲泌尿外科协会。版权所有。背景技术泼尼松龙广泛用作抗阉割前列腺癌(CRPC)的二级激素治疗。我们假设地塞米松,另一种皮质类固醇更活跃。目的比较CRPC中泼尼松龙和地塞米松的活性。设计,设定和参与者该单中心,随机阶段试验是在82名中进行的,在82名男性中进行化疗-NA've CRPC,从2006年到2010年注册。干预泼尼斯龙5毫克每日两次,每日0.5毫克每日0.5毫克与间歇性地塞米松8每天每天每天每天两次,每3周都两次。结果测量和统计分析主终点是前列腺特异性抗原(PSA)响应率。次要终点包括在PSA进展的时间,使用实体肿瘤的响应评估标准的放射学响应率(再循环)和安全性。结果和局限性在七名患者中没有响应后掉落间歇地塞米松臂。通过意图治疗,每日地塞米松与泼尼松龙的每日地塞米松的22%相比,确认的PSA响应分别观察到41%(P = 0.08)。在可评估的患者中,PSA响应率分别为地塞米松和泼尼松龙的24%,分别为24%(P = 0.05)。在泼尼松龙(危险比:1.6; 95%置信区间,0.9-2.8)上,对地塞米松的增长时间为9.7 mo。在43例可测量的疾病患者中,分别再次入学的响应率为15%和6%,分别为泼尼松龙(P = 0.6)。在PSA越过PSA进展的23名患者中,19名可评估(37%)中的7例对地塞米松的确认PSA反应。临床上显着的毒性很少见。结论地塞米松可能比CRPC中的泼尼松更活跃。在没有更明确的试验的情况下,地塞米松应优先于泼尼松龙。患者概要我们比较了两种不同的类固醇,用于治疗具有晚期前列腺癌的男性。我们的研究结果表明,地塞米松可能比泼尼松龙更有效,两者都耐受良好。临床试验登记处Eudrac 2005-006018-16背景泼尼松龙广泛用作抗阉割前列腺癌(CRPC)的二级激素治疗。我们假设地塞米松,另一种皮质类固醇更活跃。目的比较CRPC中泼尼松龙和地塞米松的活性。设计,设定和参与者该单中心,随机阶段试验是在82名中进行的,在82名男性中进行化疗-NA've CRPC,从2006年到2010年注册。干预泼尼斯龙5毫克每日两次,每日0.5毫克每日0.5毫克与间歇性地塞米松8每天每天每天每天两次,每3周都两次。结果测量和统计分析主终点是前列腺特异性抗原(PSA)响应率。次要终点包括在PSA进展的时间,使用实体肿瘤的响应评估标准的放射学响应率(再循环)和安全性。结果和局限性在七名患者中没有响应后掉落间歇地塞米松臂。通过意图治疗,每日地塞米松与泼尼松龙的每日地塞米松的22%相比,确认的PSA响应分别观察到41%(P = 0.08)。在可评估的患者中,PSA响应率分别为地塞米松和泼尼松龙的24%,分别为24%(P = 0.05)。在泼尼松龙(危险比:1.6; 95%置信区间,0.9-2.8)上,对地塞米松的增长时间为9.7 mo。在43例可测量的疾病患者中,分别再次入学的响应率为15%和6%,分别为泼尼松龙(P = 0.6)。在PSA越过PSA进展的23名患者中,19名可评估(37%)中的7例对地塞米松的确认PSA反应。临床上有毒性

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号